ADMA
ADMA
Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.
Insider Buys
4
$468K
Insider Sales
20
$17.44M
Total Volume
$17.91M
24 transactions
Net Activity
$16.97M
Net selling
Sentiment Rating
Moderate DistributionCEO Conviction Index
Liquidating / Profit Taking
Key Drivers
- •Heavy distribution: sales represent 97% of total transaction value.
- •Minor cluster buying: 2 unique insiders purchased shares.
- •CEO selling activity detected. Often driven by option expiration or diversification plans.
- •Significant liquidation: total sale value exceeds $10M.
Score Methodology
The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:
- +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
- +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
- +15CEO Buying: CEO committing own capital shows high conviction.
- +10CFO Buying: CFO purchasing shares shows financial alignment.
Elms Steve
Dir
$9.05M total
Grossman Adam S
Pres, CEO
$7.32M total
Guiheen Lawrence P.
Dir
$602K total
Grossman Jerrold B
Dir
$464K total
Tade Brad L.
CFO, Treasurer
$317K total
Quick Actions
ADMA has an insider buy conviction of 3%, compared to the Unknown sector buy average of 6%. ADMA ranks #305 in insider activity out of 570 tracked companies in its industry.
Over the last 90 days, corporate insiders at ADMA (ADMA) engaged in a total of 24 transactions reported via SEC Form 4 filings. Among these, 4 were open-market purchases and 20 were sales. The total volume of insider trading reached $17.91M.
The net insider activity for ADMA shows a net selling bias of $16.97M. This activity represents a 3% buy ratio, suggesting that insiders are currently bearish on the company's near-term outlook relative to recent history.
The most notable individual transaction was a Sale by Elms Steve (Dir), who traded 425.6K shares valued at $8.83M on Jun 12, 2025.
ADMA Biologics Inc (ADMA) Stock Forecasts
ADMA Surges 20.9% Post Q3 Earnings: Buy, Sell or Hold the Stock?
Adma Biologics (ADMA) Stock Falls Amid Market Uptick: What Investors Need to Know
ADMA Biologics (ADMA) Stock Looks Undervalued Even After A 5 Year Run
Adma Biologics (ADMA) Stock Falls Amid Market Uptick: What Investors Need to Know
Adma Biologics (ADMA) Stock Drops Despite Market Gains: Important Facts to Note
FAQs About ADMA Insider Trading
Answers to common questions regarding corporate filings and executive sentiment for ADMA.